INSM Insmed Incorporated
$94.96▲ +1.75%
Healthcare
Other
After hours
$94.96▲ +0.00%
Oct 27, 5:28 PM ET
Volume 3.35M
Avg Volume (10D) 2.88M
Key Metrics & Fundamentals
Market Cap
$20.74B
P/E Ratio
–
Div Yield
0.00%
52W Range
90.39 - 212.75
% vs 50 MA
-16.65%
% vs 200 MA
-24.81%
RSI-14
32.8
MACD Histogram
+0.1200
Beta (1Y vs SPY)
0.49
Free Cash Flow
-$95.09M
Gross Rev
$425.49M
Gross Profit
$358.27M
EBITDA
-$98.01M
COGS
$67.21M
Operating Exp
$459.58M
Operating Income
-$101.31M
EBIT
-$101.31M
Pretax Income
-$11.37M
Net Income
-$13.24M
EPS (Diluted)
-0.06
Price & Volume History
Loading chart…
Recent News
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Zacks · Oct 27, 2026 9:00 AM ET
Dimensional U.S. Equity Market ETF (DFUS) Adds Amazon and Broadcom on Thursday
GuruFocus.com · Oct 26, 2026 7:03 AM ET
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks · Oct 22, 2026 9:00 AM ET
Insmed Appoints Two New Directors to Its Board
PR Newswire · Oct 20, 2026 7:00 AM ET
Insmed Launches Brinsupri Tablet in Japan for Non-Cystic Fibrosis Bronchiectasis
MT Newswires · Oct 19, 2026 7:54 AM ET
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
PR Newswire · Oct 19, 2026 7:00 AM ET
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
PR Newswire · Oct 15, 2026 7:00 AM ET
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
PR Newswire · Oct 14, 2026 7:00 AM ET
Insmed Shares Fall After Wolfe Research Downgrade
MT Newswires · Oct 12, 2026 3:25 PM ET
Wolfe Research Downgrades Insmed to Peer Perform From Outperform
MT Newswires · Oct 12, 2026 5:31 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See INSM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.